ICU Medical, Inc. — Q3 2016 Form 10-Q
Period: Three and nine months ended September 30, 2016; unaudited. ICU Medical develops and sells medical devices for infusion therapy, critical care, and oncology. Amounts below are in U.S. dollars; financial statement figures are in millions except per-share data.
Financial performance and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Total revenue | $97.1 | $86.0 | $283.7 | $251.3 |
| Gross profit / margin | $51.3 / 52.8% | $46.3 / 53.8% | $150.6 / 53.1% | $132.5 / 52.7% |
| Operating income | $22.5 | $24.8 | $69.2 | $56.1 |
| Net income | $18.8 | $16.3 | $53.6 | $39.5 |
| Diluted EPS | $1.09 | $0.98 | $3.13 | $2.41 |
| Operating cash flow | Not stated separately for the quarter | $68.7 | $48.6 |
- Q3 revenue increased 12.9% year over year; nine-month revenue increased 12.9%. Nine-month net income rose 35.6%.
- At September 30, cash and cash equivalents were $323.0; investment securities were $106.6, including $57.2 classified as long-term. Combined cash and investments totaled $429.6, up $52.2 from year-end 2015.
- Current assets were $503.0 and current liabilities $32.5. No borrowings are presented on the September 30 balance sheet. Stockholders’ equity was $648.5.
- Nine-month investing cash outflow was $84.6, including $15.0 of capital expenditures and net purchases of investment securities. Financing cash inflow was $1.0, including $17.2 of treasury-stock purchases.
Material changes and unusual items
- Q3 operating income declined despite higher sales, partly because Q3 2015 included a $5.3 net legal-settlement gain and a $1.1 building-sale gain; neither recurred in 2016. Q3 2016 also included $2.8 of restructuring and strategic-transaction expenses and a $0.3 bargain-purchase gain. Nine-month 2016 included a $1.5 bargain-purchase gain.
- Gross margin fell 100 basis points in Q3, which management attributed primarily to higher freight and labor costs to support customer service. Nine-month margin improved 40 basis points, reflecting favorable foreign exchange and product mix, partly offset by earlier manufacturing constraints.
- Q3 direct infusion sales increased 35.1%, while OEM infusion sales decreased 22.1%, primarily due to lower Clave sales to the major OEM customer. Oncology revenue increased 38.2%; critical-care revenue increased 12.0% in Q3, although nine-month critical-care revenue declined 2.2% amid earlier production constraints.
- The estimated effective tax rate was 18% for Q3 and 25% for the first nine months, versus 35% and 31%, respectively, in 2015. The 2016 rates included discrete tax benefits from early adoption of stock-compensation accounting guidance: $3.6 in Q3 and $6.6 year to date.
- Operating cash flow benefited from increased net income; working-capital movements included higher inventory and lower accrued liabilities. The filing retrospectively reclassified excess tax benefits as operating cash flows, affecting comparability with 2015.
Outlook, transactions, and risks
- On October 6, 2016, after quarter-end, ICU Medical agreed to acquire Pfizer’s Hospira Infusion Systems business for approximately $601.0 in cash plus 3.2 million ICU Medical shares. Closing was expected in Q1 2017, subject to conditions including regulatory approvals.
- The company planned to fund the cash consideration with cash on hand and committed senior secured facilities of up to $400: a $300 five-year term loan and a $100 revolving facility. The transaction is expected to reduce cash and investments and increase leverage. The filing identifies integration, financing, regulatory, and closing risks; under specified circumstances, a $75 termination fee may be payable to Pfizer.
- Management expected existing cash and investments and future operating cash flows to fund current operations for the next 12 months, while noting that adverse business conditions or reduced investment liquidity could require alternative financing. Estimated 2016 capital expenditures were $18–$20.
- The company expected the sale of its Slovakia manufacturing facility to be completed in Q4 2016, following the planned closure and transfer of production to Mexico.
- Customer concentration remains significant: Pfizer/Hospira accounted for 26% of Q3 revenue and 31% for the first nine months; it represented 22% of receivables at quarter-end. Agreements with Pfizer extended through December 2018. Management cited dependence on large customers, ordering variability, production constraints, competition, pricing, foreign exchange, and transaction execution as risks.
- No specific earnings or revenue guidance was provided. The company reported effective disclosure controls and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether the Pfizer/Hospira acquisition closes as expected, receives required approvals, and achieves anticipated integration benefits and synergies.
- Final acquisition financing terms, post-close debt and liquidity, and any resulting constraints under the credit facilities.
- Trends in Pfizer/Hospira sales and receivables concentration, including the effect of the pending transaction and existing supply agreements.
- Whether infusion and oncology growth can offset OEM softness and critical-care production or demand challenges, and whether Q3 freight and labor pressures persist.
- The final Tangent purchase-price allocation and bargain-purchase accounting, along with the effect of the stock-compensation tax benefits on earnings comparability.
- Progress on the Slovakia facility sale and manufacturing transition, capital spending, and inventory levels.